ICP Maintains Bullish Structure Setting $4.72 as a Foundation for Next Move Higher ICP climbs 1% after testing key support, with recovery momentum suggesting further upside potential.

The release introduces the Jakarta Data specification, updates testing frameworks, and aligns with Java 21, the latest long-term support version of Java. The platform now supports Java 17 or higher ...

Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations. Elsewhere, Recursion is laying off 20% of its workforce and Gilead halted several ...

Recursion Deprioritizes 3 Clinical Programs Following Data-Driven Review, Stock Down May 05, 2025 — 08:46 am EDT Written by RTTNews.com for RTTNews -> ...

Structure content for AI search so it’s easy for LLMs to cite. Use clarity, formatting, and hierarchy to improve your visibility in AI results.

In this article, we will look at the 10 Best Performing Pharma Stocks So Far in 2025. What’s Going on in the Pharma Sector?

Recursion Announces Promising Clinical Data on Lead AI-Based Drug Candidate for Brain Disease Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in ...

The problems with real data Tech companies depend on data – real or synthetic – to build, train and refine generative AI models such as ChatGPT. The quality of this data is crucial.

Abstract: The paper describes recent improvements made to the structural recursion of the Data Funnel Interface. This end user interface organizes the raw data in a database table into a series of ...

Nvidia (NVDA)-backed Recursion Pharmaceuticals (RXRX) posts mixed results from a Phase 2 trial for its lead asset hurting AI-led biotechs. Read more here.